INTRODUCTION
Pemphigus vulgaris (PV) is a prototypical organ-specific, potentially fatal autoimmune disease of the skin, with an incidence of an estimated 0.076-5 cases in 100 000 person-years 1 that is characterized by mucocutaneous blistering. Tissue damage is mediated by autoantibodies that target self-antigens, primarily desmoglein 3 and 1, that are expressed at the surface of keratinocytes, resulting in acantholysis (loss of cell-cell adhesion) by mechanisms not fully understood. [2] [3] [4] Although there is a general consensus that the disease is multifactorial, there is a major gap in our knowledge regarding how genetic and environmental elements alter gene expression and promote disease development. Despite the very strong linkage of PV to human leukocyte antigen (HLA) DRB1*0402 and DQB1*0503, additional questions remain, such as why the vast majority of individuals who carry the PV-associated HLA susceptibility alleles do not develop the disease. Furthermore, the molecular mechanisms driving the unpredictable transitions from periods of disease activity to remission and back are not known.
Over the past several years, global genome-wide expression profiling has been useful to advance our understanding of disease mechanisms and genetic risk in a number of autoimmune diseases. [5] [6] [7] [8] [9] Although target damage in PV is within the skin, it is clear that patients exhibit systemic alterations in their peripheral immune system. 4 ,10 Thus, we undertook this study with the objectives to: (1) assign blood gene expression signatures to PV patients and HLA-matched (MCR) and -unmatched control (UMCR) subjects; (2) identify differentially expressed genes (DEGs) and investigate functional pathways and processes associated with patient and control signatures; and (3) evaluate the distribution of DEGs across the genome to identify chromosomal regions harboring transcriptional 'hot spots' that may be useful for locating disease susceptibility loci.
Our data show that unsupervised hierarchical clustering achieved distinct separation of patient and control groups, producing three distinct expression patterns characterizing (1) 'disease' (PV patients vs genetically related HLA-MCRs), (2) 'activity' (active vs remittent PV patients) and (3) 'control' (HLAmatched vs HLA-UMCRs) signatures. Functional annotation of DEGs within these signatures implicated immune pathways, cytoskeletal reorganization, apoptosis and MAPK signaling pathways in the pathogenesis of PV. Significantly, we uncovered the presence of a subset of PV-related DEGs within the PV HLArelated 'control' signature that overlapped with DEGs linked to the 'disease' signature, but that are inversely regulated (predominantly downregulated) in MCRs when compared with either PV patients or UMCRs. We propose that this subset of genes constitute a 'protection' signature in genetically susceptible control individuals who have not yet developed the disease, which serve to hold disease development in check. Analysis of the distribution of DEGs associated with the four signatures described above identified 19 transcriptional 'hot spots' that highlight chromosomal regions, which may facilitate the search for PV susceptibility genes.
RESULTS

Unsupervised hierarchical clustering and principal components analysis (PCA) achieved distinct classification of patient and control groups
We performed unsupervised hierarchical clustering on log 2 transformed, background corrected and normalized expression values from all patient (n ¼ 21; 13 PV-active (PV-A), 8 PV-remittent (PV-R)) and control (n ¼ 10; 4 HLA-MCRs and 6 HLA-UMCRs) samples. Briefly, the most variably expressed genes across the arrays were selected for hierarchical clustering. This unbiased method revealed that: (1) PV patients, regardless of disease activity or therapy status, separated away from the genetically related HLA-MCR subjects (Figure 1a ), producing a 'disease' signature, driven by 1203 most variable probes. The 21 PV patients were either off (OFF), on minimal (MIN) or more than minimal (MORE MIN) therapy, as defined by consensus Figure 1 . Unsupervised hierarchical clustering separates PV patients and healthy controls and segregates them into three distinct signatures. (a-c) Dendograms of the three signatures: (a) PV patients, regardless of disease activity and state of therapy separate from genetically matched controls (MCRs; 'disease' signature); (b) active PV patients separate from remittent patients ('activity' signature); and (c) HLA-MCRs cluster away from HLA-UMCRs ('control' signature). (d-f ) Principle components analysis displays clear spatial separation (expression level clustering) of the three assigned signatures: (d) 'disease' signature; (e) 'activity' signature; and (e) 'control' signature. In the three-dimensional plots, the three principle components PC#1, #2 and #3 of all samples and their respective variations are expressed on the x, y and z axis. The total percentage of PCA mapping variability is 42.1% for d, 74.4% for e and 59.5% for f. Each data point represents a sample. The ellipsoids highlight portioning of the different samples. Active PV (PV-A ¼ blue), remittent PV (PV-R ¼ green), HLA-MCR ( ¼ red), HLA-UMCR ( ¼ purple). Therapy status: no (OFF ¼ pink), minimum (MIN ¼ light blue) and more than minimum (MORE MIN' ¼ yellow), as defined in 'Materials and methods' . guidelines 11 and in the 'Materials and methods' section. Importantly, patients did not cluster according to therapeutic groupings (Figure 1a ), indicating that treatment did not drive the clustering. (2) PV patients with active disease as defined by consensus guidelines 11 and in the Materials and methods section (see below) were distinct from the remittent patients (Figure 1b) , delineating a disease 'activity' signature of 1572 most variable probes. For this analysis, we narrowed our patient selection to 3 PV-A and 3 PV-R patients that were off therapy (OFF) to eliminate any possible effects of on-going therapy on gene expression related to lesional activity. (3) MCR separated from UMCR ( Figure 1c ) revealing a PV HLA-related 'control' signature driven by 1915 most variable probes. Some of the top 10 GeneGO pathways and processes associated with the up-and downregulated genes driving the difference in both the 'disease' and 'activity' signatures by unbiased hierarchical clustering were immune and inflammatory response (involving interleukin-4 (IL-4), IL-13 and IL-17), cytokine production, wound healing, oxidation-reduction, apoptosis and leukocyte activation, among others ( Table 1 ). The IL-4 pathway has been shown to be intricately involved in PV pathogenesis, 12 whereas the IL-17 signaling pathway has been described relatively recently, and shown to have a critical role in inflammation and pathogenesis of multiple autoimmune diseases. 13, 14 Unique to the 'activity' signature was the enrichment of genes involved in the antiviral interferonrelated immune response. These processes and pathways are consistent with the known or suspected pathophysiological changes occurring in PV. 4, 10, [15] [16] [17] [18] Most of the top enriched GeneGO pathways and processes were also shared in the PV HLA-related 'control' signature with the notable exceptions of oxidation-reduction and apoptosis (Table 1) . We note that one clinically active patient (PV 201) did not cluster with the other active patients (Figure 1a ). On review of the clinical intake record, this patient had an atopic diathesis with multiple allergies to dust, pollen and mold as well as atopic dermatitis, which might be a reason for the grouping.
Next, to identify outliers and evaluate whether significant batch effects could be observed, PCA was performed on Log 2 transformed normalized expression indices for 454 000 transcripts of all samples in the three signatures: (1) 'disease'-all patients and HLA-MCRs; (2) 'activity'-active PV and remittent PV and (3) 'control'-HLA-matched and -UMCRs. In this analysis, all PV patients, regardless of disease activity, clearly separate away from MCRs (Figure 1d ), whereas active and remittent patients show the least separation (Figures 1d and e) . HLA-related MCRs were the most significantly clustered away from the UMCR individuals (Figure 1f ). There were no distinctive outliers.
Taken together, our data indicate that unbiased hierarchical clustering and principle components analysis can assign expression signatures associated with PV based on: the absence and presence of disease in genetically susceptible individuals ('disease' signature), variable disease phases ('activity' signature) and HLA association ('control' signature). In addition, we clearly demonstrate that the transcriptional grouping of patients is driven by disease state, and not by therapy status or gender.
The 'disease' signature DEGs were generated by comparing the groups that produced the 'disease' signature by the unbiased approach (see above). Table 2 .
Functional annotation and pathway analysis of the DEGs within the 'disease' signature revealed a significant enrichment of dysregulated pathways and processes involving regulation of actin cytoskeleton, regulation of stress-activated protein kinases in the MAPK signaling pathway, clathrin-coated vesicle transport cycle, apoptosis, G-protein signaling pathways including p38MAPK, c-Jun N-Terminal Kinase (JNK) and RhoA showing most genes upregulated in PV patients as opposed to MCR (Figure 2b ). We found a total of 67 DEGs involved with apoptosis and cell death (mostly upregulated) in PV patients vs MCRs; Apoptotic pathways have been implicated in Table 1 . Potentially disease relevant GeneGo pathways and processes (within the top 10 significant pathways) associated with the up and downregulated genes driving the differences in the 'disease' , 'activity' , and 'control' signatures by unsupervised hierarchical clustering the induction of acantholysis in a number of studies. 15, 16, 19, 20 Fortytwo protein kinases and nine protein phosphatases were dysregulated. Many of these pathways and specific DEGs support documented events in PV pathogenesis. 15 Of note, we observe a 2.47-fold upregulation in PV patients of ATP2C1 (calcium-transporting ATPAse type 2C member 1), which has been associated with Haley-Haley disease 21 and PV. 22 Both diseases are characterized by a loss of cell-cell adhesion because of desmosomal dysfunction, which may be linked to the altered intracellular calcium metabolism associated with the gene. 22, 23 Also, ADAM9 (fold change (FC) ¼ 2.2), a membrane-anchored metalloprotease related to disintegrins has been shown to mediate proteolysis of the E-cadherin cell adhesion molecules and DSG1, 24, 25 processes central to the development of nonmucosal blisters in PV. 26 We observed additional enriched pathways and processes such as neurotrophin signaling (IRS2, BRAF, FOXO3, PTPN11, IRAK3, NRAS, BDNF, MAP3K5, MAP3K1, GAB1, RIPK2, MAPK9, FOXO3B and FRS2), membrane fusion (SNAP29, PLDN, GNAI3, RABIF, NAPG, BNIP1, RABEP1, VTI1B, LRMP, VAMP3, SNAP23 and GCA) and sphingolipid metabolic process (ACER3, SGMS2, GLA, COL4A3BP, PPP2CA, SGMS1, NSMAF, CLN8 and SFTPB) that have not previously been associated with disease.
The 'activity' signature In order to evaluate transcriptional changes directly associated with different phases of clinical activity, we next eliminated control subjects from the comparison. Although unsupervised clustering showed that the therapeutic regimen did not affect how patients clustered (see above and Figure 1a ), to avoid any therapeutic bias, we included only those six patients, three active (PV-A) and three remittent (PV-R), which were completely off therapy (OFF) for further analysis. Hierarchical clustering of 252 DEGs generated from this comparison separated the six samples into their corresponding phenotype (data not shown) with 203 up and 49 downregulated transcripts in active vs remittent patients (Supplementary Table 1 ). The top 10 DEGs are shown in Figure 3a . See Supplementary Table 3 for the full DEG list.
More than 30 DEGs, mostly upregulated in active vs remittent patients, are enriched for gene ontology pathways and processes related to immunity (innate and adaptive immune response) such as the nucleotide-binding oligomerization domain-like receptor signaling pathway along with cytokine production and interaction, inflammatory pathways, apoptosis, leukocyte and lymphocyte activation, and are consistent with 'activity'-associated functional pathways and processes revealed by unsupervised clustering analysis. Activated immune response was the most highly enriched process (Figure 3b ), followed by oxidation reduction with 19 DEGS (ME2, SORD, FADS1, NCF4, PYROXD1, SCD, UGDH, PDIA5, ALDH3B1, NDUFV3, SCCPDH, NPHP3, CYP4A11, PRUNE2, TP53I3, DHFR, PLOD1, H6PD and PNPO). Upregulation of pathways and processes such as cytokine-cytokine receptor interaction (10 DEGs), inflammation pathway involving Jak-signal transducer and activator of transcription (STAT) signaling (7 DEGs) and apoptosis (5 DEGs) was observed. In addition, we found an enrichment of the Ras-related G-protein, RACI signaling pathway, with three DEGs (C3orf10, PAK1 and NCF2). Most DEGs in all the enriched pathways and processes were upregulated in active patients when compared with patients in remission ( Figure 3b ).
We also note significant enrichment of six DEGs (IRAK1, SLC11A1, NOD2, CARD9, SCARB1 and MGST1) associated with the GO biological process; 'response to molecule of bacterial origin' that is of interest because of the recent association of host gene-microbiota interactions with blistering disease of the skin. The PV HLA-associated 'control' signature PV exhibits one of the strongest known HLA disease associations, where 495% PV patients type as HLA DRB1*0402 and DQB1*0503 positive. 4, 10 However, a large percentage of healthy individuals who carry these two alleles do not develop disease. 10 To uncover differences in transcriptional activity in healthy HLA-matched individuals (MCR, carrying the PV-associated DRB1*0402 and/or DQB1*0503 alleles) from healthy HLA-unmatched subjects (UMCR, carrying neither DRB1*0402 nor DQB1*0503), we eliminated all diseased subjects from the next analysis. Hierarchical clustering of 534 DEGs generated from this comparison separated the 10 samples into their corresponding phenotype (data not shown) with 163 up and 371 downregulated transcripts (Supplementary Table 1 6). Functional annotation and pathway analysis of this subset of 155 shared DEGs revealed pathways, processes and networks such as G-protein signaling-associated RhoA (ARGEF3, EPHA8, GNAQ, PFAS), RAC1 (ARHGAP12, PFAS, LCP2), and JNK pathways (MAP3K5, MAP4K4, MAPK9, MAP3K2), apoptosis (MAP3K5, NSMAF, GNAQ, MAPK9, LEPROT, and SMAD2), cell cycle regulation (CD16), cytoskeleton remodeling (PFAS, SMAD2), immune response (PSMA2, ACTN2, ARPC5, MAPK9, LCP2), keratinocyte differentiation (MAP3K5, GNAQ, SMAD2) cell adhesion (EPHA8, MAP4K4) and inflammation (ATF1, MAPK9). Based on the discovery of this unique subset of DEGs associated with the PV HLA-related 'control' signature that exhibit overlapping, but inverse regulation in MCR when compared with either PV patients or UMCR, we propose the existence of a potential 'protection' signature in individuals who carry PV-associated HLA risk alleles but remain disease free. For the full list of 155 DEGs with FCs in MCR vs PV-A and PV-R as well as MCR vs UMCR see Supplementary Table 5 . Interestingly, three DEGs (IL13RA1, OGFRL1 and CNPY3) overlapped between the 'protection' and 'activity' signatures and were downregulated in MCR vs all PV patients (PV-A þ PV-R) as well as UMCR. Furthermore, these three DEGs were also downregulated in remittent PV patients vs active PV patients. A detailed list of 'disease-,' 'activity-,' 'control-' and 'protection-'associated DEGs that have been linked to PV and/or other autoimmune diseases is included in Supplementary Table 6 .
Confirmation of microarray results
To confirm the altered expression levels of genes detected by microarray, we performed quantitative real-time PCR of cDNA derived from the total RNA of selective active and remittent PV patients and HLA-matched and HLA-unmatched healthy controls (classified in the exact same manner as the initial set of test samples).
The trend of relative FCs in gene expression from quantitative reverse transcription PCR was consistent with our microarray findings (Supplementary Table 7 ). Although the extent of FCs varied to a degree between the quantitative reverse transcription PCR and microarray results, the directionality of the differential expression patterns was the same in all cases, supporting the reliability of the microarray analysis. A representative example of the results for PTPN22 is shown in Supplementary Figure 1. PV-associated DEGs overlap with previous microarray studies We next compared DEGs associated with the 'disease,' 'activity,' 'control' and 'protection' signatures to previously published PV-related global gene expression signatures in patients and in vitro. The most comparable study was the microarray validation analysis by Sarig et al., who reported 175 DEGs comparing nine newly diagnosed (untreated) PV patients with nine age-and population-MCR individuals. Thirteen DEGs (mostly upregulated) in the 'disease' and six DEGs (all upregulated) in the 'activity' signatures reported in our study are common to the Sarig et al. study 28 (Supplementary Table S8A and B). One DEG, GAS7 (Growth-arrest specific 7), overlapped between the 'protection' signature and the microarray analysis of the Sarig et al. study where it was upregulated in patients vs controls. In our study, GAS7 was also upregulated in PV patients as well as in UMCR when compared with MCR. We also found four dysregulated genes, CD33 ('activity' signature), DSC2 ('activity' signature), CTSB ('disease' signature) and USP34 ('disease' signature), which overlapped with three earlier, in vitro microarray studies, which were performed by exposing either human or murine keratinocytes to PV patient serum. [29] [30] [31] Mapping of DEGs to the genome To better understand the distribution of PV-associated dysregulated genes across the genome, we leveraged our gene expression data to identify transcriptional 'hot spots' at which the DEGs map with statistically increased frequency than would be expected by chance using the 'genome' tool within the dCHIP software. All significant gene stretches with X4DEGs at p1% false discovery rate (FDR) level were designated as 'hot spots'. Seven 'hot spots' were found within the 'disease' signature: 2p16.1-p13.1, 4q13.2-q22.1, 9p11.2-q21.13, 11q14.3-q22, 14q21.3-q23.1, 15q14-q21.1 and 22q11.1-q12.3. Six transcriptional 'hot spots' associated with the 'activity' signature were found on chromosomes 1q21. Figure 2) . No 'hot spots' were associated at p1% FDR level with the 155 DEGs of the 'protection' signature. However, when the criteria of inclusion were changed to p5% FDR, two significant gene stretches with X3DEGs were observed on chromosomes 3p14.3 and 14q21.2-q24.1. Although 60 DEGs across the four PV-associated signatures map to chromosome X Figure 6 . Hierarchical clustering of 'protection' signature was processed using the Euclidean distance algorithm in Partek Genomic Suite. In the heat map, red indicates upregulation while blue indicates downregulation and gray indicates no change. The samples cluster into HLA-matched controls (MCR ¼ red) and PV patients and HLA-unmatched controls (PV-A þ PV-R þ UMCR ¼ teal). Two distinct clusters of genes are observed: (1) a group of 132 genes, which are downregulated in MCR when compared with PV-A þ PV-R þ UMCR and (2) a group of 23 genes upregulated in MCR when compared with PV-A þ PV-R þ UMCR. Expression value intensities are illustrated by the color of the scale with a range of À 4 to þ 4 on a log scale.
(none mapped to chromosome Y), no transcriptional 'hot spot' was found.
Overall, 183 DEGs were included in the 19 'hot spots' across the four PV-related signatures ( Table 2) . Three of these, OSM ('activity' signature), OLIG1 ('activity' signature) and USP34 ('disease' signature), overlapped with previously reported PV-related DEGs. 28, 29 We also uncovered one dysregulated gene, GPD1L (Chr3p22.3) ('disease' signature), upregulated in PV patients vs HLA-MCRs, which did not map to any 'hot spot', but coincided with a recently reported potential non-HLA disease susceptibility gene. 28 
DISCUSSION
The varied incidence of PV across populations, strong association with HLA class II subtypes and recent identification of putative disease susceptibility genes provide strong support for a genetic basis for PV. 10, [32] [33] [34] [35] The heterogeneous nature of the disease makes it necessary to use multivariate techniques in an attempt to make associations between clinical observations and underlying molecular and genetic perturbations. Unbiased analysis of microarray data from peripheral blood of PV patients and control subjects produced unique gene signatures in our study, thus revealing a method for molecular classification of patients through 'class prediction' (categorizing samples by disease state). The 'disease' signature clearly distinguishes PV patients from genetically related HLA-MCRs, a contrast with the potential to delineate gene markers relevant to disease induction. The 'activity' signature separates active from remittent stages of disease, and genes within this signature may be important for understanding disease progression and prognosis and for identifying biomarkers to monitor treatment success in reverting patients to a lesionfree state. The PV HLA-related 'control' signature distinguishes healthy individuals that type as HLA DRB1*0402 and/or DQB1*0503 positive (HLA matched) from those that do not (HLA unmatched). The unanticipated identification of a subset of DEGs that overlaps between the 'control' and the 'disease' signature, but based on opposite directionality of regulation separates HLA-MCRs from both HLA-unmatched healthy individuals as well as active and remittent PV patients-termed the 'protection' signature here-represents an example of 'class discovery' whereby molecular methods reveal a previously unknown classification.
Functional annotation and pathway analysis of the DEGs in the PV-associated 'disease' and 'activity' transcriptional signatures underscore dysregulated genes and pathways significant to genetic susceptibility, induction, expression and progression of the disease. The G-protein signaling pathway, which includes RhoA, p38MAPK and JNK enriched in the 'disease' signature, is associated with triggering apoptosis and acantholysis in keratinocytes. [36] [37] [38] [39] [40] The kinases in the MAPK pathway, relevant to adaptive immunity, respond to external stimuli (mitogens, stress and proinflammatory cytokines). Activation of signaling through both protein kinase C isoforms and MAPK has been proposed to initiate acantholytic changes by affecting changes in desmosomes as well as reorganization in the cytoskeleton. 15, 29, 37, 38, 41 The large number (42 DEGs) of generic/protein kinases and phosphatases found is of significance because phosphorylation and dephosphorylation of key effector molecules and adhesion complexes by them and phosphatases have been suggested to have a major role in acantholysis. 42 Alterations in the actin cytoskeleton constitute one of the major processes proposed to be involved in PV-IgG-induced keratinocyte dissociation. The relevance of these changes in peripheral blood remains to be interpreted. Overall, the transcriptional data within the 'disease' signature represent a step forward in delineating diagnostic markers relevant to PV and provide insights into mechanisms relevant to disease development. The large number of DEGs between patients and controls emphasizes the clinical heterogeneity and multifactorial nature of PV. Abbreviation: PV, Pemphigus vulgaris. DEGs in bold overlapped with previously reported PV-related transcripts.
Genome-wide expression analysis in Pemphigus vulgaris R Dey-Rao et al
In the 'activity' signature, we observed an overall upregulation of transcripts associated with immune mechanisms, inflammatory processes, G-protein signaling pathways, oxidation reduction and apoptosis that are emphasized in patients with heightened clinical activity as compared with those in a quiescent phase of disease. These data establish molecular classification of defined PV clinical states and suggests potential prognostic markers for disease flares. The observed enrichment of the NOD-like receptor signaling pathway with four DEGs (PYCARD, NOD2, IL18 and CARD9) reflects an activated immune system in PV patients with active lesions. The upregulation of 19 DEGs in the enriched oxidation-reduction process may indicate enhanced oxidative stress on-going at the systemic level during phases of increased lesional activity. Interestingly, our group has recently found a statistically significant decrease in total antioxidant capacity in serum from PV patients vs control individuals (manuscript in preparation). Finally, the observed upregulation of transcripts in the RAC1-associated G-protein signaling pathway reflects an involvement in cytoskeleton remodeling and cell polarity, [43] [44] [45] which are major processes involved in PV-IgG-induced keratinocyte dissociation.
Within the PV HLA 'control' signature, we found six dysregulated genes in the muscarinic cholinergic receptors, ACM/ACM3-related pathways. The cholinergic system has been shown to modulate intercellular adhesion by targeting cadherins and integrins, 46, 47 and it has been reported that acantholysis in pemphigus can occur because of anti-acetylcholine receptor antibodies in keratinocyte monolayer. [48] [49] [50] The significant enrichment of the KEGG pathway 'spliceosomes' with eight DEGs was noteworthy due to an autoimmune response against essential components within the spliceosomes that is associated with rheumatoid arthritis and systemic lupus erythematous. 51 Most interestingly, of the 158 overlapping DEGs found between the 'disease' and 'control' signatures, a subset of 155 were regulated in the opposite direction in MCR when compared with either all PV patients or UMCR. Both PCA analysis and hierarchical clustering revealed that this set of 155 genes distinguished MCR from all PV patients (PV-A þ PV-R) as well as UMCR. We propose that this set of 155 genes may constitute a 'protection' signature relevant to preventing the expression of PV in MCR individuals that carry the highly disease-linked HLA risk alleles DRB1*0402 and DQB1*0503. The dysregulated pathways and processes enriched among this subset of 155 DEGs are related to G-protein signaling, immune response, apoptosis, cell cycle regulation, keratinocyte differentiation, cell adhesion and inflammation, among others which are central to PV pathogenesis. 15, 36, 45, [52] [53] [54] Within the 'protection' signature, several transcripts such as ARHGEF3, IL13RA1, SMAD2, PTPN22 and CNPY3 have been shown to have a role in inflammatory and autoimmune diseases. These five molecules are highlighted as examples of genes whose upregulation may contribute to operational pathways in PV and other autoimmune diseases, and whose downregulation in MCR whether compared with PV patients or UMCR may indicate a protective mechanism in genetically susceptible but symptomfree individuals. Moreover, IL13RA1, OGFRL1 (opioid growth factor receptor-like 1) and CNPY3 were found to overlap between the 'protection' and 'activity' signatures and found to be downregulated in MCR when compared with either all PV patients or UMCR as well as downregulated in remittent PV patients when compared with active PV patients. This may suggest a role of IL13RA1, OGFRL1 and CNPY3 in both disease protection and in prevention of lesional activity. Studies using larger cohorts of patients and healthy controls involving immunohistopathology, analysis of serum protein levels and mechanistic studies are needed to validate our results and the existence of the 'protection' pattern. For DEGs within the 'disease,' 'activity,' 'control' and 'protection' signatures with previously described relevance to PV and/or other autoimmune/inflammatory diseases see Supplementary Table 6 .
The case for disease relevance of specific genes and pathways may be strengthened for genes that are dysregulated across analyses. There are four DEGs which overlap all four signatures (IL13RA1, KIF13A, OGFRL1 and CNPY3) and are involved in immune response, B-cell proliferation and IL-13/IL-4 signaling pathway in inflammation. Furthermore, genes that are dysregulated across studies may be particularly relevant for disease pathogenesis. Thirteen DEGs (ACSL1, PTGS1, CA2, F5, PFKFB3, FAM198B, GADD45A, GAS7, GPR27, IL1R2, IRAK3, OLIG1 and PDK4) were found common between the 'disease' signature reported here and recent microarray-based transcriptional data by Sarig et al., 28 and are involved in enriched pathways and networks associated with apoptosis, inflammatory and innate immune response, supporting their role in PV pathogenesis. 15, 17 Six common DEGs were found between the 'activity' signature reported here and the Sarig et al. study, 28 namely, OSM, CES1, CKAP4, DSC2, SLC11A1 and OLIG1. These genes were upregulated in active patients in both studies and are involved in pathways and networks associated with immune response, phagocytosis, cell adhesion and cell junctions.
It has been demonstrated that genes that are highly transcriptionally dysregulated are likely to be altered at the DNA level. 55 It can be expected that in at least some cases transcriptional variance observed in disease represent the downstream functional consequences of disease-associated genetic variations. Chen et al. 55 proposed using gene expression data to influence the prioritization of target candidate genes for single-nucleotide polymorphism in genome-wide association studies. As such, we transposed our transcriptional data set onto the physical genome map and identified 19 transcriptional 'hot spots' representing a total of 183 DEGs associated with the four PV-related signatures described in this report. Functional annotation and pathway analysis of the 183 'hot spots'-related DEGs revealed significant associations with PV-related pathways, processes and networks such as apoptosis, cytoskeletal remodeling, immune and inflammatory response, as well as male sex differentiation. Three of these 'hot spots'-related DEGs (OSM, OLIG1 and USP34) were identified in earlier microarray analyses in PV. 28, 29 In addition, GPD1L (glycerol-3-phosphate dehydrogenase 1-like; FC ¼ 2.1) was the one DEG common between our study ('disease' signature) and a suspected nonmajor histocompatibility complex susceptibility locus in PV. 28 A defect in GPD1L has been associated with various forms of inherited arrhythmia. 56 None of the other recently reported 35 putative non-major histocompatibility complex susceptibility loci in Israeli Jewish PV patients were found to be transcriptionally dysregulated in our study. Transcriptional 'hot spots' identified in this study may house as yet unknown PV susceptibility loci. The candidates identified from this study may help to inform future research to identify individuals predisposed to PV. For more information on the DEGs with putative roles in either PV and/or other autoimmune/inflammatory diseases, see Supplementary  Table 6 .
In conclusion, the analyses presented here advance efforts to better understand the molecular and genetic basis of autoimmunity in the skin. PV is a polygenic and multifactorial disease. The reasons for a breach of immunological tolerance are not known but may involve environmental/infectious trigger factors in addition to genetic factors and immune dysregulation. Current knowledge suggests a working model for PV where self (or cross reaction foreign)-antigen is presented in the context of major histocompatibility complex class II molecules to CD4 þ T cells, which then activate antigen-specific B cells to produce skinspecific autoantibodies. Autoantibodies target epidermal antigens (mainly desmoglein 3, and in some cases desmoglein 1) to cause the classic disease pathology (acantholysis, suprabasal split of the epidermis, blister formation and erosions) by mechanisms not yet fully understood. The genes and pathways revealed by genome-wide expression analysis lend support to the steps along this putative disease pathway, revealing dysregulation in innate and adaptive immune processes, responses to viral and bacterial molecules, leukocyte and B-cell activation, and cytokine/chemokine/stress pathway activation, and further illuminate additional genes and functional pathways with potential relevance to disease (Figure 7) . The role of apoptosis in PV is unresolved to date, but recent data indicate that apoptotic signaling pathways may be activated in the skin after antibody binding. 16 How these phenomena relate to the dysregulation of apoptotic molecules in the blood revealed by this study remains to be determined. The discovery of specific transcriptional profiles or 'signatures' assigned to clearly defined patient and control subgroups has clinical relevance to disease classification and provides insights into disease mechanisms and genetic susceptibility. Extended microarray analysis in larger data sets and further defined clinical subgroups will be needed to validate the expression patterns described in this report and identify actionable biomarkers and genetic risk elements with direct utility, perhaps incorporating longitudinal study design. Most significantly, our finding that a set of disease-associated genes is downregulated in HLA-matched individuals as compared with either PV patients or UMCR subjects suggests the novel and provocative hypothesis that this signature serves a protective function in genetically susceptible individuals and may harbor targets that could be potentially manipulated to thwart, or even reverse, disease. Table 9 ) according to previously published consensus guidelines. 11 Minimal therapy (MIN) is defined as less than, or equal to, 10 mg per day of prednisone (or the equivalent) and/or minimal adjuvant therapy for at least 2 months. 'OFF' therapy is defined as being off all systemic therapy for at least 2 months.
MATERIALS AND METHODS
Patient recruitment and tissue handling
Demographic information, duration of disease and treatment history were obtained from each subject at the time of sampling. The PV patient group consisted of 15 females and 6 males (2.5:1 ratio). The female/male ratio was maintained in the healthy control group with seven females and three males (2.3:1 ratio). The average age of the PV patients was 48.9 years ( ± 10.3) and that of the controls was 44.9 years ( ± 11.7). There were 25 Caucasians, 1 Asian, 2 African Americans and 3 individuals of Hispanic origin included in the study. Full study subject information is provided in Supplementary Table 9 .
Ficoll gradients (Amersham Biosciences, Piscataway, NJ, USA) were used to extract peripheral blood mononuclear cells from collected blood samples. Specimens were immediately frozen at À 80 1C immediately for subsequent RNA extraction (see below).
HLA typing
HLA allele typing at DRB and DQB loci was completed at the Tissue Typing laboratory of Michigan State University, by PCR amplification using sequence-specific primers as described by Olerup and Zetterquist. 57 Patients and controls were grouped into 'HLA matched' (either homo-or heterozygous expression of the PV-associated alleles DRB1*0402 and/or DQB1*0503) 34 or 'HLA unmatched' (expressing any other HLA class II alleles than DRB1*0402 and DQB1*0503; see Supplementary Table 9 ).
RNA extraction
Procedures for RNA extractions and cDNA synthesis were followed as described before. 5, 58 Briefly, total RNA was isolated from peripheral blood Figure 7 . A schematic representation of the disease process in PV supported by some of the differentially expressed genes (DEGs) and pathways revealed by microarray analysis. DEGs from the 'disease' signature are listed in black, whereas DEGs from the 'activity' signature are listed in red. Microarray data analysis
The Human Genome U133 Plus 2.0 microarray platform was used to generate gene expression profiles from blood samples obtained from a total of 31 patients and controls. Initially, MAS5 statistical algorithm was used for probe set summarization using the Affymetrix Expression Console software to assess the data quality of all 31 samples through a set of quality control indicators. No outliers were identified. Gene expression data were then imported to Partek Genomics Suite v6.6 (Partek, St Louis, MO, USA) as CEL files using default parameters. Robust multiarray average analysis was used to perform raw data preprocessing, which included log 2 transformation, quantile normalization, background correction and median polish probe set summarization. Average expression levels were distributed similarly across all samples.
Unsupervised clustering of variable genes
Unsupervised hierarchical clustering was performed on the most variable log 2 transformed, background corrected and normalized expression values using a flat include cut-off filter of Coefficient of variation (CV)X0.2 across all 31 samples. To study the effect of therapy status on unsupervised clustering of variable genes in the PV-A þ PV-R þ MCR sample group, the hierarchical cluster was overlaid with known therapy status. We used PCA on the three signatures discovered by unsupervised hierarchical clustering to check for outliers and to observe specific batch effects based on disease state (PV-active and remittent) and controls (matched and unmatched). Both these unsupervised methods do not consider known sample attributes such as disease activity, state or therapy status while organizing the data. We superimposed sample information using color coding.
DEGs and pathway analysis
In the three signatures ('disease', 'activity' and 'control') clearly separated by unsupervised hierarchical clustering, DEGs were detected using oneway analysis of variance model, implemented in Partek Genomics Suite along with Fisher's Least Significant Difference contrast method used to compare two groups of samples. FC cut-off was 4 ± 2.0 for the 'disease' signature, and 4 ± 1.5 for 'activity' and 'control' signatures. The P-values generated by the comparisons were then corrected using a Benjamini Hochberg 59 (step-up) false discovery rate of 1% and 2% for 'disease' and 'control' signatures, respectively, or selected with an uncorrected P-value of o0.05 for the 'activity' signature.
Trimmed DEG lists (removing duplicates) with gene symbols were matched to GO molecular functions, biological processes, cellular components and KEGG pathways via DAVID (http://david.niaid.nih.gov), 60 as well as GeneGO network objects, pathway maps, processes and networks via Metacore v6.9 tool (GeneGo Inc., Thomson Reuters, St Jospeh, MI, USA; http://www.genego.com). 61 The statistical significance of pathways, processes and networks was calculated using the Hypergeometric test where the null hypothesis assumes that no difference exists between the numbers of genes in a given pathway in the target DEG list and the genome as a whole. A list of enriched annotations and pathways with P-value less than 0.05 and including at least two to five genes were included. We used a comparative enrichment workflow in MetaCore for the DEG list generated from comparing PV-A þ PV-R vs MCR ('disease' signature) with MCR vs UMCR ('control' signature) and compared all four signatures with each other as well.
We analyzed each of DEG lists for chromosomal enrichments by leveraging our gene expression data to identify regions of the chromosomes with a statistically significant proportion of DEGs, to detect transcriptional 'hot spots'. The DEGs in each list generated were analyzed in the context of all genes on the array for its chromosomal location enrichment using DNA-Chip Analyzer (dCHIP; www.dchip.org). Duplicate probe sets were masked for gene mapping using the 'genome' tool.
Confirmation of microarray results using quantitative reverse transcription PCR Total RNA from human (patients and controls) blood was made using the PAXgene Blood RNA Kit (Qiagen Inc.) according to manufacturer's recommended protocol including DNase treatment. RNA was quantified by fiber optic spectrophotometry by Nanodrop ND-1000 (Thermo Scientific, Wilmington, DE, USA) and an A 260 /A 280 absorbance ratio X2.0 was taken as inclusion criteria.
We used an entirely new set of PV patients and healthy controls (classified as PV-active, PV-remittent patients, as well as HLA-matched and HLA-unmatched healthy controls, in the same manner as in the initial test set of samples) for this analysis. cDNA was synthesized from 400 ng total RNA using the Promega Kit (Promega Corp., Madison, WI, USA) and quantitative real-time PCR was subsequently carried out using the FastStart Universal SYBR Green Master (ROX) from Roche (Roche Diagnostics, Mannheim, Germany) according to carefully standardized protocols. Intron-spanning primers were designed using Primer3 v4.0 (http:// primer3.wi.mit.edu/) for the following selected DEGs: THAP1, PTPN22 ('protection'), TLR4, IL1R2 ('disease'), PLEKHA1 ('activity') and VNN1 ('control') based on published human gene sequences in the Ensemble Genome Browser (http://useast.ensembl.org/index.html). Amplicons were designed to be less than 150 bp in most cases. Reactions were run in triplicates from PV-A þ PV-R (n ¼ 4), MCR (n ¼ 3) and UMCR (n ¼ 2), and the experiments repeated twice. The resulting reverse transcription-PCR cycle times were normalized against the b-actin (ACTB) housekeeping gene and FCs in expression were calculated using the 2 À DDCT method 62 relative to one sample of the control taken as unity. The resulting relative FCs in gene expression were compared with those obtained by microarray analysis.
